The impact of this transition is already becoming evident across the life sciences industry. The global 3D cell culture market is expected to increase from approximately US$1.4 billion in 2026 to nearly US$2.3 billion by 2033. This surge shows the growing adoption of 3D cell culture technologies as pharmaceutical and biotechnology companies seek more predictive preclinical research models.
The Growing Role of 3D Cell Culture in Drug Research
In April 2025, the U.S. Food and Drug Administration (FDA) published a roadmap stating its intent to make animal testing "the exception rather than the norm" for preclinical drug safety assessment, beginning with monoclonal antibodies before extending to other drug classes. The agency committed to accepting AI-based computational toxicity models, human cell assays, and organoid-based testing, collectively known as New Approach Methodologies, in place of the animal studies that regulatory filings have relied on for decades.
A year later, the FDA reinforced its commitment by releasing a progress report. In April 2026, it highlighted the first year's achievements under the roadmap. The report also introduced a searchable database of accepted New Approach Methodologies (NAMs), giving drug developers clear guidance on where and how these methods can be used. That database matters more than it might first appear.
The new guidance gives companies a better understanding of how animal-free testing methods can be used, reducing the uncertainty that previously limited their adoption. With more transparent regulatory expectations, drug developers can plan long-term research and clinical programs with greater confidence, making this policy change more impactful than the launch of any single new technology.
3D Cell-Based Assays Are Becoming the Default Language of Preclinical Screening
The regulatory shift is no longer limited to the U.S. The European Chemicals Agency has been encouraging the same transition, particularly in cosmetics and chemical testing, where animal testing bans are already strict. Hence, the demand is increasing for advanced research technologies that support reliable, animal-free testing and help companies meet evolving regulatory requirements.
This transition is also reflected in the growing adoption of cell-based assays. According to Persistence Market Research, North America accounted for around 42.5% of the global market in 2025, supported by favorable regulations and the early adoption of AI-powered imaging technologies. Leading pharmaceutical companies are integrating advanced 3D human cell models into their preclinical research to generate results that better predict human responses.
AstraZeneca's Cambridge research unit has already built collaborations with organoid specialists to fold 3D human-derived assays into its preclinical pipeline, aiming for results that translate more reliably into human trials. When a company of that level restructures its own pipeline around 3D models rather than treating them as a supplementary check, this shows the growing role of 3D cell culture as a core technology in modern preclinical drug development rather than a supplementary research tool.
Major Life Science Companies Are Investing in Organoid Technology
Rising demand for advanced research models is encouraging leading life science companies to strengthen their organoid capabilities through strategic acquisitions and technology investments. In January 2025, for example, the Life Science business of Merck KGaA completed its acquisition of HUB Organoids, a Netherlands-based company holding a foundational patent portfolio in organoid technology. The acquisition expanded Merck's capabilities by adding HUB's organoid generation and high-throughput screening technologies to its existing portfolio of cell culture media, reagents, and laboratory instruments.
Other established players are moving in parallel. InSphero has broadened its 3D InSight human liver microtissue platform to support more predictive toxicology and metabolism studies. These developments show that organoid and spheroid technologies are no longer viewed as experimental. As regulatory support and pharmaceutical demand continue to surge, established life science companies are investing in these advanced research platforms to meet evolving industry needs.
Patient-Derived Organoids Are Turning Cell Culture into a Clinical Decision Tool
One of the most significant advancements is taking place in personalized cancer treatment. Scientists are now using tumor organoids grown from a patient's own biopsy tissue to evaluate how different cancer drugs may perform before treatment begins. Because these organoids closely replicate the genetic and cellular features of the original tumor, they provide more accurate insights than traditional cell lines or animal models.
This progress adapts with the growing focus on precision medicine, where demand for personalized therapies continues to rise. As patient-derived organoids become more widely used in clinical research and treatment planning, 3D cell culture is evolving beyond drug discovery and playing an important role in supporting personalized healthcare decisions.
Where 3D Cell Culture Technology is Headed Next
The future of drug development will likely be shaped by technologies that deliver more predictive, human-relevant results while meeting evolving regulatory expectations. As the FDA's New Approach Methodologies (NAMs) framework gains wider acceptance and similar initiatives expand across Europe and Asia Pacific, demand for validated 3D cell culture platforms is expected to accelerate.
